<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Febri Kurniawati</style></author><author><style face="normal" font="default" size="100%">Sony Wibisono Mudjanarko</style></author><author><style face="normal" font="default" size="100%">Soebagijo Adi Soelistijo</style></author><author><style face="normal" font="default" size="100%">Titong Sugihartono</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Association of Triglyceride and Glucose Index with Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Hepatic steatosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Insulin resistance</style></keyword><keyword><style  face="normal" font="default" size="100%">NAFLD</style></keyword><keyword><style  face="normal" font="default" size="100%">TyG index</style></keyword><keyword><style  face="normal" font="default" size="100%">Type 2 diabetes mellitus</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">1077- 1080</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Non-alcoholic fatty liver disease (NAFLD) is significantly linked to obesity, insulin resistance (IR), metabolic syndrome, and type 2 diabetes (T2DM). There isn't a single biomarker used to diagnose NAFLD. &lt;strong&gt;Objectives:&lt;/strong&gt; Analyzing the association between triglyceride and glucose index (TyG) with NAFLD in T2DM. &lt;strong&gt;Methods: &lt;/strong&gt;This cross-sectional study aimed to assess the efficacy of TyG as a potential NAFLD biomarker. The study was conducted on 103 diabetes outpatient clinics at the Dr. Soetomo General Academic Hospital from August to October 2023. Sixty-seven subjects experienced steatosis, while those who did not experience steatosis were 36. The statistical analysis used in this study is binary logistic regression with p &amp;lt;0.05. &lt;strong&gt;Results:&lt;/strong&gt; The receiver operating characteristic curves (ROC) analysis showed a TyG cut-off value of 9.334 (AUC = 0.660). Analysis of the risk of TyG on the incidence of steatosis was carried out using binary logistic regression. The results showed that TyG was a significant risk factor for steatosis. Patients with a TyG value above 9.334 risk developing steatosis 3.567 times greater than patients with a TyG value below 9.334 (OR 95% = 1.373 – 9.270, p = 0.009). &lt;strong&gt;Conclusion: &lt;/strong&gt;A significant association between TyG and NAFLD in T2DM patients, which the TyG index may be a more effective, valuable, and uncomplicated measure for detecting and controlling NAFLD.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">1077</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Febri Kurniawati&lt;sup&gt;1,2&lt;/sup&gt;, Sony Wibisono Mudjanarko&lt;sup&gt;3,4*&lt;/sup&gt;, Soebagijo Adi Soelistijo&lt;sup&gt;3,4&lt;/sup&gt;, Titong Sugihartono&lt;sup&gt;3,5&lt;/sup&gt; &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Internal Medicine Subspecialty Study Program, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Division of Gastroentero-Hepatology, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA&lt;/p&gt;
</style></auth-address></record></records></xml>